| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.29 | 0.09 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.47 | 0.09 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |